ArticleAvicenna journal of phytomedicine
Synergistic effects of oxypeucedanin and temozolomide on viability, proliferation, apoptosis, and migration of T98G malignant glioblastoma cells.
Article in Avicenna journal of phytomedicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interactions of ACEA and WIN 55,212-2 mesylate with temozolomide and cisplatin in neuroblastoma and glioblastoma cell lines: an isobolographic analysis.Pharmacological reports : PR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Glioblastoma multiforme (GBM), an aggressive primary brain tumor, distinguished by an invasive growth pattern and resistance to current therapeutic strategy. This study investigates the potential of Oxypeucedanin (OP) as a natural compound to induce apoptosis and inhibit proliferation in T98G GBM cells, either alone or in combination with Temozolomide (TMZ). Materials and Methods: T98G cells were exposed to OP and TMZ individually and in combination. Then, cell viability (MTT assay), cell proliferation (using trypan blue), mRNA expression (qRT-PCR), Cell cycle and apoptosis (flow cytometry), and migration (wound healing assay) were evaluated. Results: The viability assays revealed that both OP and less potentially TMZ decreased cell viability in a time- and dose-dependent manner. Notably, the combination of OP and TMZ demonstrated synergistic effects, substantially enhancing apoptosis rates while reducing proliferation, as evidenced by reduced cell growth rates and altered cell cycle distribution towards G2/M arrest. Additionally, gene expression analysis indicated increased Conclusion: This study suggests the potential of OP as a complementary therapeutic agent alongside TMZ for GBM treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.